Identification of a G protein-coupled receptor for 11(R),12(S)-epoxyeicosatrienoic acid and its effects in the cardiovascular system

11(R),12(S)-环氧二十碳三烯酸G蛋白偶联受体的鉴定及其对心血管系统的影响

基本信息

项目摘要

Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) enzymes as different regioisomers and play a central role in cellular processes including Ca2+ signalling, hyperpolarization, intracellular communication, angiogenesis, and the prevention or resolution of inflammation as well as the control of vascular tone and blood pressure. Work from our group has demonstrated that 11,12-EET seems to be the biologically more active of the regioisomers and able to elicit rapid cellular responses, the fastest in endothelial cells being the translocation of transient receptor (TRP) C3/C6 channels to caveolae. Exactly how 11,12-EET initiates cell signalling has yet to be resolved. Despite this there is a considerable amount of circumstantial evidence to indicate that a specific G protein coupled membrane receptor for 11,12-EET; more specifically 11(R),12(S)-EET, exists: (1) high affinity EET binding sites have been detected on the surface of some cells, (2) different EET stereoisomers, and regioisomers show distinct biological effects, (3) stable and specific EET agonists and antagonists have been generated to mimic or prevent the actions of 11,12-EET, (4) 11,12-EET induced cellular responses; such as cell proliferation, gap junctional communication or TRP channel translocation, are absolutely reliant on the activation of protein kinase A (PKA), moreover, (5) the downregulation of Gs but not Gq/11 proteins abolishes endothelial cell sensitivity to 11,12-EET. Identifying a receptor for 11(R),12(S)-EET receptor is not straight forward given that the agonist is a fatty acid epoxide, this means that many classical binding studies and labelling approaches used to identify peptide receptors are not easily applicable. Also although many of the effects of the EETs rely on PKA activation, the EET-induced changes in cyclic AMP tend to be small and inconsistent, particularly in endothelial cells.In preliminary studies it has been possible to demonstrate GPR124 as a candidate 11,12-EET receptor in endothelial cells. Indeed, the downregulation of GPR124 abolishes the 11,12-EET-induced translocation of TRPC6 channels as well as 11,12-EET-induced endothelial cell proliferation (responses to VEGF were unaffected) and endothelial cell sprouting. These effects correlated with changes in the cellular distribution of the receptor. Our hypothesis is that GPR124 is the receptor for 11(R),12(S)-EET and is required for the biological actions of the epoxide in endothelial cells. The aims of this project are to (1) determine whether GPR124 displays characteristics of a receptor for 11,12-EET by assessing its sensitivity to EET analogues (so called EET agonists and antagonists), as well as receptor desensitization, internalization and recycling, (2) determine the downstream signals activated by GPR124 in the presence of 11,12-EET, and (3) to determine whether the deletion of GPR124 in adult mice alters biological responses to 11,12-EET.
环氧二十碳三烯酸(EETs)是由细胞色素P450(CYP)酶以不同区域异构体的形式由花生四烯酸合成的,在细胞内钙信号、超极化、细胞内通讯、血管生成、预防或消除炎症以及控制血管张力和血压等过程中发挥着核心作用。我们小组的工作表明,11,12-EET似乎是区域异构体中生物学上更活跃的,能够引起快速的细胞反应,在内皮细胞中,最快的是瞬时受体(Trp)C3/C6通道移位到小窝。11,12-EET是如何启动细胞信号转导的还有待解决。尽管如此,有大量的间接证据表明,11,12-EET的G蛋白偶联膜受体,更具体地说,11(R),12(S)-EET,存在:(1)在一些细胞表面检测到高亲和力的EET结合部位,(2)不同的EET立体异构体,并且区域异构体显示出不同的生物学效应,(3)已经产生了稳定和特异的EET激动剂和拮抗剂来模拟或阻止11,12-EET,(4)11,12-EET诱导的细胞反应;如细胞增殖、缝隙连接通讯或Trp通道转位,都完全依赖于蛋白激酶A(PKA)的激活。此外,(5)Gs蛋白的下调而不是GQ/11蛋白的下调使内皮细胞对11,12-EET的敏感性消失。确定11(R),12(S)-EET受体的受体并非易事,因为激动剂是脂肪酸环氧化物,这意味着许多用于识别多肽受体的经典结合研究和标记方法并不容易应用。此外,尽管EET的许多作用依赖于PKA的激活,但EET诱导的环状AMP的变化往往很小且不一致,特别是在内皮细胞中。在初步研究中,GPR124可能是内皮细胞中11,12-EET的候选受体。事实上,GPR124的下调取消了11,12-EET诱导的TRPC6通道的移位以及11,12-EET诱导的内皮细胞增殖(对血管内皮生长因子的反应不受影响)和内皮细胞的萌发。这些效应与受体细胞分布的变化有关。我们的假设是GPR124是11(R),12(S)-EET的受体,是环氧化物在内皮细胞中发挥生物学作用所必需的。本项目的目的是(1)通过评估GPR124对EET类似物(所谓的EET激动剂和拮抗剂)的敏感性以及受体的脱敏、内化和再循环来确定GPR124是否显示出11,12-EET受体的特征,(2)确定GPR124在11,12-EET存在的情况下激活的下游信号,以及(3)确定成年小鼠GPR124的缺失是否改变了对11,12-EET的生物反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professorin Dr. Ingrid Fleming, Ph.D.其他文献

Professorin Dr. Ingrid Fleming, Ph.D.的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Professorin Dr. Ingrid Fleming, Ph.D.', 18)}}的其他基金

Vascular complications of type 2 diabetes: tyrosine phosphorylation of the endothelial nitric oxide synthase (eNOS)
2 型糖尿病的血管并发症:内皮一氧化氮合酶 (eNOS) 的酪氨酸磷酸化
  • 批准号:
    165772555
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
    Research Grants
General costs relating the administration of the Research Unit
与研究单位行政管理有关的一般费用
  • 批准号:
    22341101
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
    Research Units
Angiotensin converting enzyme (ACE): defining its role as a signal transduction molecule
血管紧张素转换酶(ACE):定义其作为信号转导分子的作用
  • 批准号:
    5402052
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
    Research Units
Deciphering the role of soluble epoxide hydrolase in homeostasis with Chemical Biology tools
使用化学生物学工具解读可溶性环氧化物水解酶在体内平衡中的作用
  • 批准号:
    530858826
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
    Research Grants

相似国自然基金

有翅与无翅蚜虫差异分泌唾液蛋白Cuticular protein在调控植物细胞壁免疫中的功能
  • 批准号:
    32372636
  • 批准年份:
    2023
  • 资助金额:
    50.00 万元
  • 项目类别:
    面上项目
原发性开角型青光眼中SIPA1L1促进小梁网细胞外基质蛋白累积升高眼压的作用机制
  • 批准号:
    82371054
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
  • 批准号:
    82370976
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
细胞周期蛋白依赖性激酶Cdk1介导卵母细胞第一极体重吸收致三倍体发生的调控机制研究
  • 批准号:
    82371660
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
  • 批准号:
    82371798
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
  • 批准号:
    82370865
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
紧密连接蛋白PARD3下调介导黏膜上皮屏障破坏激活STAT3/SNAI2通路促进口腔白斑病形成及进展的机制研究
  • 批准号:
    82370954
  • 批准年份:
    2023
  • 资助金额:
    47.00 万元
  • 项目类别:
    面上项目
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
  • 批准号:
    82371738
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目

相似海外基金

Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia
DOR-KOR 异聚体介导的外周镇痛变构分子的鉴定
  • 批准号:
    10608439
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
New 5HT2AR Target Identification and Assay Development for Discovering Psychoplastogenic Compounds
用于发现精神质体化合物的新 5HT2AR 靶标鉴定和检测开发
  • 批准号:
    10742536
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Identification of osteoclast endocrine and paracrine communications by systems genetics approaches
通过系统遗传学方法鉴定破骨细胞内分泌和旁分泌通讯
  • 批准号:
    10716388
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Comprehensive identification of E3 ubiquitin ligases that degrade heart, lung, and blood-relevant transcription factors
全面鉴定可降解心脏、肺和血液相关转录因子的 E3 泛素连接酶
  • 批准号:
    10677457
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Identification of small molecule NPBWR1 agonists
小分子 NPBWR1 激动剂的鉴定
  • 批准号:
    10726549
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Identification of bacterial small molecule inhibitors of Proteus mirabilis urease activity
奇异变形杆菌脲酶活性细菌小分子抑制剂的鉴定
  • 批准号:
    10348347
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Identification of CaMKII as a novel substrate of dopaminylation following heroin self administration
CaMKII 鉴定为海洛因自我给药后多巴胺酰化的新型底物
  • 批准号:
    10555211
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
  • 批准号:
    10704557
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Identification of bacterial small molecule inhibitors of Proteus mirabilis urease activity
奇异变形杆菌脲酶活性细菌小分子抑制剂的鉴定
  • 批准号:
    10609445
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Identification of Cyclic Peptide Antagonists of an Anti-Opioid G Protein-Coupled Receptor
抗阿片G蛋白偶联受体环肽拮抗剂的鉴定
  • 批准号:
    10256110
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了